MEMPHIS, Tenn.--(BUSINESS WIRE)--GTx, Inc. (Nasdaq: GTXI) announced today that the effects of Ostarine™ (GTx-024) on physical function in patients with non-small cell lung cancer (NSCLC) will be the subject of an oral podium presentation at the 14th Annual World Conference on Lung Cancer, the annual meeting of the International Association for the Study of Lung Cancer being held July 3 – 7 in Amsterdam, The Netherlands. Ostarine is an oral selective androgen receptor modulator (SARM) which GTx is evaluating for the prevention and treatment of muscle wasting in patients with NSCLC.
